Since end of December 2021, the race for vaccines against Covid-19 is in full swing. While pharmaceutical companies value the performance of their serums, none of them has yet managed to agree on the prices of the latter, which are constantly rising.
AstraZeneca’s return to France
On Friday March 19, 2021, the High Authority for Health (HAS) updated its recommendations for the AstraZeneca vaccine. Taken up by the Ministry of Health, they indicate that it presents a “possible risk”Among those under 55. A major turnaround, as people aged 65 and over could not claim this injection.
The latter was suspended Monday, March 15, 2021 for three days, due to a possible link with “atypical” cases of thrombosis in European patients, leading to increased vigilance. Following the HAS declaration, Jean Castex announced that the bites would resume the same day. “Following the opinion of the EMA, the HAS-santé gives the green light to the resumption of vaccination with AstraZeneca for people aged 55 and over”, Declared in turn Olivier Véran on his Twitter account.
A panel of anti-Covid vaccines
Johnson & Johnson, Sanofi, Moderna, AstraZeneca, Pfizer… Laboratories are fighting a fierce struggle to develop and market their vaccines. If some are already on the market, others are still under review by the EMA, like the German CureVac or the Russian Sputnik V.
While most laboratories agree that two doses are necessary (with a more or less long interval between each dose), other elements also come into play when it comes to comparing vaccines: the storage temperature (-70 ° for Pfizer-BioNTech, between 2 and 8 ° for AstraZeneca, or even -20 ° for Moderna) and the efficacy rate (95% for Pfizer patients and 94.1% for Moderna, after the injection of two intramuscular doses, 70% for AstraZeneca).
And that’s without counting on the price differences. While many vaccines cost more than ten euros per dose (€ 15.50 for the Pfizer-BioNTech vaccine, € 15 for Moderna, € 10 for CureVac…), AstraZeneca for its part displays an unbeatable price. , up to € 2.
A short-term increase?
During a virtual Barclays Global HealthCare Conference meeting two weeks ago, two executives of the Pfizer group – CFO Frank d’Amelio and senior vice president of investor relations, Chuck Triano – announced that the price of their vaccine could increase. The latter has not been set in relation to normal market prices. According to Business Insider media outlet, “the pharmaceutical giant could increase the prices of the vaccine when the Covid-19 goes from a pandemic state to an endemic situation and the virus circulates continuously in certain pockets of the world”.
“If you look at how current demand and current prices are determined, it is clear that they are not determined by what I would call normal market conditions or normal market forces… They are determined by the pandemic situation. in which we find ourselves and by the needs of governments to procure doses from various vaccine suppliers”, affirmed Frank D’Amelio.
But this price increase would not only be reserved for the vaccine from the Pfizer group. Moderna or even Johnson & Johnson would have “discreetly announces their intention to increase the prices of the vaccines against the coronavirus”, Reveals The Intercept. The online magazine reports conversations that would have been linked between pharmaceutical groups and investors, during conferences organized by banks, like Raymond James or Barclays. According to the financial directors of the laboratories, the virus could well become endemic, and eventually require new reminders, in particular in the context of the fight against variants. Significant profit possibilities for these laboratories.